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The Duffy antigen/receptor for chemokines, DARC, belongs to the family of atypical heptahelical chemokine receptors that do not
couple to G proteins and therefore fail to transmit conventional intracellular signals. Here we show that during experimental auto-
immune encephalomyelitis, an animal model of multiple sclerosis, the expression of DARC is upregulated at the blood–brain barrier.
These findings are corroborated by the presence of a significantly increased number of subcortical white matter microvessels staining
positive for DARC in human multiple sclerosis brains as compared to control tissue. Using an in vitro blood–brain barrier model we
demonstrated that endothelial DARC mediates the abluminal to luminal transport of inflammatory chemokines across the blood–
brain barrier. An involvement of DARC in experimental autoimmune encephalomyelitis pathogenesis was confirmed by the observed
ameliorated experimental autoimmune encephalomyelitis in Darc/ C57BL/6 and SJL mice, as compared to wild-type control
littermates. Experimental autoimmune encephalomyelitis studies in bonemarrow chimeric Darc/ andwild-typemice revealed that
increased plasma levels of inflammatory chemokines in experimental autoimmune encephalomyelitis depended on the presence of
erythrocyte DARC. However, fully developed experimental autoimmune encephalomyelitis required the expression of endothelial
DARC. Taken together, our data show a role for erythrocyte DARC as a chemokine reservoir and that endothelial DARC contributes to
the pathogenesis of experimental autoimmune encephalomyelitis by shuttling chemokines across the blood–brain barrier.
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Introduction
Multiple sclerosis is the most common inflammatory demyelinating
disease of the CNS with unknown aetiology to this date. Much of
our current knowledge about multiple sclerosis pathogenesis has
been obtained from its animal model experimental autoimmune
encephalomyelitis (EAE). In EAE CD4 + auto-aggressive T cells
are activated outside of the CNS. To gain access to the CNS,
where they start the molecular events leading to inflammation,
oedema formation and demyelination, T cells have to breach the
endothelial blood–brain barrier. Interaction of auto-aggressive
immune cells with the blood–brain barrier endothelium has there-
fore been recognized as a major pathophysiological hallmark of
EAE and multiple sclerosis. In fact, inhibition of immune cell traf-
ficking into the CNS with the humanized anti-4-integrin antibody
natalizumab is a successful therapeutic regimen for the treatment
of multiple sclerosis (Engelhardt and Kappos, 2008).
The recruitment of T cells across the inflamed blood–brain bar-
rier during EAE is mediated by the sequential interaction of differ-
ent adhesion and/or signalling molecules on the immune cell and
the blood–brain barrier endothelium. P-selectin/PSGL-1-mediated
rolling and 4b1-integrin/VCAM1-mediated capture of encephali-
togenic T cells on the brain endothelium is followed by 4b1-in-
tegrin-VCAM1 and LFA-1–ICAM1/2-mediated T cell arrest on the
blood–brain barrier. This is followed by LFA-1-ICAM1/2 mediated
T cell polarization and T cell crawling on the blood–brain barrier
against the direction of blood flow with the aim to find a site
permissive for diapedesis across the blood–brain barrier
(Engelhardt and Ransohoff, 2012).
In addition to integrins and their endothelial ligands of the im-
munoglobulin superfamily there is a large body of evidence sug-
gesting that chemokines are critically involved in the migration of
inflammatory cells across the blood–brain barrier during EAE and
multiple sclerosis. Chemokine binding to their respective G-protein
coupled receptors on the leucocyte surface leads to the inside-out
activation of constitutively expressed integrins on the leucocyte
surface. Activated intergins display an increased affinity and avid-
ity, which is prerequisite for integrin-mediated firm adhesion of
immune cells to the vascular endothelium. Live cell imaging studies
have provided evidence that integrin-mediated stable adhesion of
encephalitogenic T cells in CNS microvessels requires G-protein
coupled receptor signalling (Vajkoczy et al., 2001; Piccio et al.,
2002). To act on the circulating T cells, the chemokines must be
available at the luminal surface of the blood–brain barrier. Luminal
presence of CCL2 and CCL5 on the blood–brain barrier has been
suggested by live cell imaging studies demonstrating that antibo-
dies blocking CCL2 and CCL5 prevented leucocyte adhesion but
not rolling in the inflamed brain microvasculature during EAE (dos
Santos et al., 2005). In addition, EAE studies in mice with genetic
deletions of the chemokine receptors CCR1 (Rottman et al.,
2000), CCR2 (Fife et al., 2000; Izikson et al., 2000) or CXCR2
(Carlson et al., 2008) have indicated that these molecules and
their respective ligands—CCL5, CCL2 and CXCL1 (Roy et al.,
2012)—are involved in EAE pathogenesis. In apparent contrast
to their involvement in inflammatory cell entry into the CNS
during EAE, expression of CCL2, CCL5 and CXCL1 was found
to be mainly localized to astrocytes within the CNS parenchyma,
rather than to brain endothelial cells (Ransohoff et al., 1993;
Miyagishi et al., 1997; Glabinski et al., 1999). If these chemokines
therefore function to mediate inflammatory cell entry into the CNS
parenchyma during EAE it is mandatory that they could breach the
endothelial blood–brain barrier from the abluminal to the luminal
side.
In contrast to blood vessels in peripheral organs, the highly
specialized endothelial cells forming the blood–brain barrier inhibit
transcellular or paracellular diffusion of inflammatory mediators by
their extremely low pinocytotic activity and an elaborate network
of complex P-face associated tight junctions between the endo-
thelial cells (Engelhardt and Sorokin, 2009). These physical barrier
characteristics protect the CNS parenchyma from the constantly
changing milieu in the blood stream and thus maintain CNS
homeostasis, which is prerequisite for the proper function of neu-
rons. At the same time the blood–brain barrier endothelium estab-
lishes a functional barrier by the expression of transporters and
enzymes, which strictly control the import of nutrients from the
blood stream into the CNS and the export or degradation of me-
tabolites out of the CNS (Engelhardt and Sorokin, 2009). Thus,
availability of inflammatory chemokines derived from CNS paren-
chymal cells on the luminal blood–brain barrier critically relies on
the availability of a chemokine transport system allowing CNS
expressed chemokines to breach the blood–brain barrier from
the abluminal to the luminal side.
One such transport system could be the Duffy antigen receptor
for chemokines (DARC). DARC belongs to a family of silent seven-
transmembrane spanning receptors, which because of the lack of
the DRYLAIV consensus motif in the second intracellular loop, do
not couple to G proteins and therefore do not transmit intracellular
signals like other G-protein coupled chemokine-receptors leading
to integrin activation or cell motility (Novitzky-Basso and Rot,
2012). DARC binds to a broad range of inflammatory chemokines
of both the CC and the CXC chemokine families, but does not
interact with homeostatic chemokines (Gardner et al., 2004).
DARC is expressed on erythrocytes, cerebellar neurons and most
importantly on postcapillary venule and capillary endothelial cells
in a number of peripheral organs including lymph nodes
(Kashiwazaki et al., 2003), the lung (Lee et al., 2003), and the
kidney, but not on arterial endothelial cells (Middleton et al.,
2002). In these organs, endothelial DARC is therefore specifically
expressed in the vascular segment involved in leucocyte extrava-
sation. In fact, DARC was shown to mediate chemokine transcy-
tosis from the basolateral to the luminal side of the endothelium,
where the chemokines remain immobilized on the tips of endo-
thelial apical microvilli and enhance leucocyte trafficking in vivo
(Pruenster et al., 2009).
Expression of DARC at the blood–brain barrier has not been
described. Here we investigated expression of DARC in blood–
brain barrier endothelium. We found that DARC is induced in
blood–brain barrier endothelium before onset of clinical EAE and
in multiple sclerosis in vivo and that brain endothelial DARC can
shuttle inflammatory chemokines from the abluminal to the lu-
minal surface of an in vitro blood–brain barrier model.
Contribution of DARC in EAE pathogenesis was confirmed by an
ameliorated disease course in Darc/ SJL/J and Darc/ C57BL/
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6 mice compared with wild-type littermates. EAE experiments in
reciprocal bone marrow chimeric mice demonstrated that although
increased plasma levels of inflammatory chemokines observed
during EAE depended on the presence of erythrocyte DARC,
amelioration of EAE required the absence of endothelial DARC.
Taken together, our data confirm a role for erythrocyte DARC
as a chemokine reservoir and demonstrate that endothelial
DARC contributes to EAE pathogenesis by shuttling chemokines
across the blood–brain barrier.
Materials and methods
Mice
Mice were bred in individually ventilated cages at specific pathogen-
free conditions according to the animal protection law of the Kanton
Bern, Switzerland. Breeding of mice and all animal experiments shown
in this study have been approved by the veterinary office of the
Kanton Bern. Wild-type SJL/J HanHsd (SJL) or C57BL/6 JOlaHsd
(C57BL/6) mice were purchased from Harlan, AD Horst, The
Netherlands. Darc/ mice (Dawson et al., 2000) were characterized
previously and shown to lack expression of functional DARC protein.
Darc/ mice were backcrossed into C57BL/6 or SJL background for a
minimum of 10 generations before use in experiments. The genotype
of mice was confirmed by PCR as described (Dawson et al., 2000).
Reciprocal bone marrow chimeric mice were generated by reconsti-
tuting lethally irradiated C57BL/6 or Darc/ C57BL/6 mice (10 grey)
with 1  106 up to 2.5  106 isolated total bone marrow cells of non-
irradiated donor mice of either C57BL/6 wild-type or Darc/ C57BL/6
mice. Recipient mice were used at 12 to 14 weeks of age and bone
marrow donor mice were used at the age of 12 weeks to 6 months.
After bone marrow reconstitution, mice were kept in individually venti-
lated cages on autoclaved bedding. Mice received trimethoprim
(0.16 mg/ml) and sulfamethoxazole (0.8 mg/ml) within their drinking
water as a precaution. Mice were used for experiments 6–8 weeks
after reconstitution.
Human tissue
Human brain tissues were obtained from post-mortem autopsies sup-
plied by the UK Multiple Sclerosis Tissue Bank (UK Multicentre
Research Ethics Committee, MREC/02/2/39), funded by the Multiple
Sclerosis Society of Great Britain and Northern Ireland (registered char-
ity 207495). Cortical tissue with subcortical white matter from five
cases without any diagnosed neurological disease was taken as con-
trols. These subjects had an average age of 69.4 years [21.5 stand-
ard deviation (SD)] and an average post-mortem time of autopsy was
14.2 h (6.98 SD). Cortical tissues from nine cases with multiple scler-
osis with average disease duration of 28.75 years (11 SD) were used
for this study. Their average age was 56 years (15.98 SD), and an
average post-mortem time of autopsy was 13.67 h (6.73 SD).
DARC-positive blood vessels in subcortical white matter in mul-
tiple sclerosis and control cases were counted using the ‘cell counter’
in ImageJ and assessed per cm2. An unpaired t-test was performed
with the data for all multiple sclerosis cases (n = 10 tissue sam-
ples of nine cases) and control cases (n = 8 tissue samples of five
cases).
Experimental autoimmune
encephalomyelitis
Active EAE was induced in 8–12-week-old C57BL/6 wild-type and
Darc/ C57BL/6 mice or in bone marrow chimeric mice 6 to 8
weeks after reconstitutions, as described previously (Engelhardt
et al., 2005; Doring et al., 2007). Active EAE in Darc/ SJL and
wild-type SJL mice was induced as described (Engelhardt et al.,
2005; Doring et al., 2007). Weight and clinical disease were assessed
daily and scored as: 0 = healthy, 0.5 = limb tail, 1 = hind leg weakness,
2 = hind leg paraplegia, 3 = hind leg paraplegia and incontinence. Mice
with more severe EAE scores were sacrificed as requested by the vet-
erinary office of the Kanton Bern and are therefore not included into
this study.
Antibodies
Supernatants of the hybridomas Hermes-1 (9B5, anti-human CD44,
used as an isotype-matched control) and M1/9 (anti-mouse CD45)
were produced in our own laboratory and used undiluted. Mec13.3
(anti-mouse PECAM1) was a gift of Dr E. Dejana (IFOM, Milan, Italy).
A polyclonal rabbit anti-mouse DARC antibody against the C-terminus
(amino acids 319–333: LPRQASQMDALAGK) as previously published
(Kashiwazaki et al., 2003) was prepared by Sigma-Genosys, Sigma
Aldrich. Purified IgG fractions of the antisera were obtained by protein
A affinity chromatography. Specific recognition of DARC by the poly-
clonal IgG fraction was confirmed by positive immmunoreactivity on
spotted peptides, western blots of lymph nodes and specific staining of
high endothelial venules of peripheral lymph nodes in frozen tissue
sections of wild-type mice and absence of this staining in Darc/
mice. Secondary antibodies used were Alexa Fluor 488 goat-anti
rat IgG, Cy3 goat anti rat IgG, biotin goat anti-rat IgG combined
with AMCA-streptavidin and Cy3-goat anti rabbit IgG (all from
Jackson ImmunoResearch Laboratories).
Immunofluorescence staining
Immunofluorscence staining of mouse tissue sections and on
pMBMECs (primary mouse brain microvascular endothelial cells)
were performed as described previously (Pfeiffer et al., 2008, 2011;
Steiner et al., 2011).
Immunohistochemistry on human brain
tissue
Cryostat sections (12mm) of fresh frozen human post-mortem cortical
tissue were fixed in 4% paraformaldehyde for 10 min at 4C. For in-
activation of endogenous peroxidise, sections were treated with 0.6%
hydrogen peroxide in methanol for 30 min and blocked with blocking
buffer (1% normal donkey serum, 0.1% Triton, 0.05% Tween) for
1 h. Sections were incubated with the following primary antibodies
overnight at 4C: mouse anti-human DARC (generous gift from Dr
M. Uchikawa, Japanese Red Cross, Tokyo, Japan, 1:200), mouse anti-
MOG (clone Z12, kindly provided by R. Reynolds, 1:100), mouse anti-
CD68 (Abcam Ab845, 1:50) and mouse anti-CollagenIV (Cemicon,
1:2000). Secondary botinylated antibodies (Vector Laboratories,
1:500) were applied for 2 h at room temperature, followed by ABC
complex reagent (Vector Labs) for 30 min. Colour reaction was per-
formed with 3-amino-9-ethylcarbazole. Cells were stained in haema-
toxylin for 5 min and rinsed afterwards under running tap water.
1456 | Brain 2014: 137; 1454–1469 C. Minten et al.
by guest on April 7, 2015
D
ow
nloaded from
 
In situ hybridization
In situ hybridization was performed as described (Alt et al., 2002).
Briefly, single-stranded 35S-labelled antisense or sense RNA-probes
were generated by in vitro transcription using T3 or T7 RNA polymer-
ases as described by the manufacturer (Stratagene). The probe for in
situ hybridization was prepared from the I.M.A.G.E. Consortium
(Lennon et al., 1996) complementary DNA Clone IMAGE:718084.
The Darc complementary DNA EcoRI/NotI fragment was subcloned
into pBluescript II KS + (Stratagene). Expression of Darc messenger
RNA was investigated in sections of brain and spinal cord derived
from two different SJL/N mice with EAE (Day 14 and Day 17 post-im-
munization, clinical score 2 and 3, respectively) and from two different
healthy age-matched control mice. Specificity of the hybridization sig-
nals was verified by the use of sense probes on serial control sections.
After hybridization, slides were coated with photographic emulsion
(Kodak NTB-2) and exposed for 4 weeks. After fixation, sections
were counterstained with Toluidine blue, dehydrated, mounted and
analysed with dark and bright field microscopy.
Quantitative polymerase chain reaction
analysis
RNA extraction, complementary DNA synthesis and quantitative real-
time PCR analysis using SYBR Green were performed in triplicates as
described (Lyck et al., 2009). The following primer pairs were used:
Pair 1: primer 911 (50-CTTCACCTTGGGACTCAGTGT-30) and primer
912 (50-GACTGGCAGCCCTAAGAGG-30). Pair 2: primer 913 (50-AGT
GTCCTGGGCATGCTG-30) and primer 914 (50-CTGCCAGTGGAAGA
AAGGTC-30). Negative control complementary DNA samples without
reverse transcriptase enzyme were assayed in parallel. As reference s16
ribosomal protein messenger RNA was included using the following
primer pair: sense GATATTCGGGTCCGTGTGA; reverse TTGAGAT
GGACTGTCGGATG.
T cell proliferation assay
In vitro antigen-recall assays to test for antigen-specific proliferation of
T cells was determined by measuring 3H-thymidine incorporation into
the DNA of proliferating T cells as previously described (Engelhardt
et al., 1998; Doring et al., 2007).
In vitro chemokine transport across the
blood–brain barrier
For in vitro chemokine transcytosis, pMBMECs were isolated from
brains of DARC-deficient and wild-type SJL mice at 6–8 weeks of
age, as described (Steiner et al., 2010). pMBMECs plated on
Matrigel (BD Biosciences) coated 0.4 mm pore size transwell filters
(Corning; Vitaris AG) and cultured for 6 days to reach confluency.
Optionally, pMBMECs were stimulated for 16–18 h with recombinant
mouse TNF- (12.5 ng/ml). Endothelial cell-derived chemokine pro-
duction was assayed from samples taken before the experiments.
pMBMECs were washed once in minimal assay medium [Dulbecco’s
modified Eagle medium (4500 g/l glucose), 5 % (v/v) newborn calf
serum, 25 mM HEPES, 4 mM L-glutamine] and 100 ml fresh minimal
assay media was applied to the upper chamber. Fifty nanograms per
millilitre of the respective recombinant mouse chemokines (R&D
Systems Europe Ltd) added to 600ml minimal assay media into the
lower chamber and incubated at 37C, 10% CO2. At 1-, 2- and 3-h
time points the filter inserts were removed to stop chemokine
transport and 50 ml samples were taken from the upper chambers
and immediately frozen at 20C. After addition of 50 ml fresh min-
imal assay media to the upper chamber, filter inserts were placed back
into the lower compartment and the assay was further incubated until
the next time point. At the 3-h time point the assay was stopped and
50 ml samples were taken from the upper and lower chambers. Filter
inserts were washed twice in PBS, fixed for 2 h in formalin gas phase
and Giemsa stained [10 % (v/v) Giemsa solution in tap water; Sigma
Aldrich] for 30 min. Cells were air-dried overnight and mounted on
glass slides. Endothelial monolayer confluency was analysed by light
microscopy. All conditions were assayed in triplicates.
Detection of chemokines in mouse
plasma
Mice were anaesthetized and blood was collected by retro-orbital
bleed. Heparin (5000 U/ml) was added immediately and blood samples
were centrifuged (3000g) for 15 min at 4C. Translucent blood plasma
was collected and stored at 20C. Detection of chemokines in
mouse plasma was performed using a mouse cytokine array (R&D
Systems Europe Ltd) according to the instructions provided by the
manufacturer.
Analysis of chemokine concentrations
by ELISA
Chemokine concentrations in blood plasma or in samples from che-
mokine transcytosis assays were determined by ELISA (R&D Systems
UK) according to the protocol provided by the manufacturer. Data
were analysed using GraphPad Prism software, calculating values
using a four-parameter sigmoidal curve fit model.
Permeability assay
Barrier function of pMBMEC monolayers was studied as described
(Steiner et al., 2011).
Statistics
All statistical analyses were performed using Graph Pad Prism 4.0 soft-
ware for Macintosh. If not indicated differently, data are presented as
mean  SD and Student’s t-test was performed to compare different
data sets. Asterisks indicate significant differences (*P5 0.05;
**P5 0.005; ***P5 0.001).
Results
Expression of DARC is induced in
microvascular endothelial cells of
the CNS before onset and during
experimental autoimmune
encephalomyelitis
In a previous gene expression profiling study aiming to identify
genes involved in the migration of inflammatory cells across the
blood–brain barrier during EAE, we identified upregulated expres-
sion of DARC in cerebral microvessel preparations from C57BL/6
DARC in EAE Brain 2014: 137; 1454–1469 | 1457
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and SJL mice with EAE when compared with microvessel prepar-
ations from healthy control mice (Alt et al., 2005). Subtractive
suppression hybridization and subsequent sequencing corrobo-
rated induction of DARC in inflamed microvessels during EAE
(Alt et al., 2005).
As DARC belongs to the family of atypical chemokine receptors,
its upregulation in inflamed CNS microvessels during EAE sug-
gested its involvement in the transport of CNS chemokines to
the luminal surface of brain endothelial cells and consequent
leucocyte recruitment across the blood–brain barrier (Pruenster
et al., 2009). To localize DARC expression to the endothelial
cells of CNS microvessels we performed in situ hybridizations on
frozen brain sections of SJL mice with EAE and of healthy SJL
mice. We found expression of Darc messenger RNA in brain
endothelial cells of inflamed venules in mice suffering from EAE
but not in the brains of healthy SJL mice (Fig. 1). We also con-
firmed expression of Darc messenger RNA in cerebellar neurons as
previously described (Horuk et al., 1996).
To validate the expression of DARC in endothelial cells of
inflamed CNS microvessels at the protein level, we generated a
polyclonal rabbit anti-mouse DARC antibody. Immunofluorescence
staining for DARC on frozen brain and spinal cord sections of SJL
and C57BL/6 mice at different time points after induction of EAE
was combined with staining for PECAM1 to identify endothelial
cells and staining for CD45 to localize inflammatory cells. The first
detectable immunofluorescent signal for DARC on PECAM1 +
endothelial cells of brain and spinal cord venules was already
observed at Day 7 after induction of EAE in both C57BL/6 and
SJL mice (Fig. 2, Supplementary Fig. 1 and data not shown). At
that time clinical EAE had not yet started and only sparse CD45 +
inflammatory cells were present in the CNS. On Day 11 post-im-
munization at the onset of clinical EAE we observed immunofluor-
escence for DARC on PECAM1 + endothelial cells of brain and
spinal cord venules surrounded by CD45 + inflammatory cell infil-
trates. Additional immunofluorescence for DARC was observed on
PECAM1 + endothelial cells in venules not surrounded by inflam-
matory cells. At Day 13 or 14 post-immunization during ongoing
EAE immunofluorescence for DARC was not further increased and
restricted to venules surrounded by inflammatory cuffs (Fig. 2 and
Supplementary Fig. 1). Taken together these findings suggest that
expression of DARC is induced in endothelial cells of CNS venules
after the induction of EAE before immune cell recruitment across
the blood–brain barrier and might contribute to cellular infiltration
of the CNS.
Increased expression of DARC in
multiple sclerosis white matter
To investigate whether DARC is also expressed in multiple scler-
osis, immunohistochemistry was performed on post-mortem mul-
tiple sclerosis brain tissues of nine cases with multiple sclerosis
analysing chronic active and chronic inactive lesions and compared
to five control cases without any diagnosed neurological disease.
DARC-positive blood vessels were detected in inflammatory
demyelinating lesions (Fig. 3B), identified by lack of myelin
(Fig. 3A) and inflamed vessels (Fig. 3C), in meninges, and in
normal appearing white matter in multiple sclerosis as well as in
inflamed white matter microvessels of control cases characterized
by the presence of CD68 + macrophages/activated microglia
(Fig. 3). Activated microglia in multiple sclerosis and control
white matter is frequently observed in post-mortem brain tissue,
but no direct correlation with DARC immunoreactivity could be
identified. Comparison with collagen IV immunostaining (Fig. 3E),
expressed by all CNS vessels, revealed DARC expression in
a subset of microvessels in multiple sclerosis and in controls
(Fig. 3F). Interestingly, control cases showing signs of neurode-
generative diseases other than multiple sclerosis accompanied by
chronic inflammation such as Alzheimer’s disease (detection of tau
aggregates) or hypoxia also presented with increased numbers of
DARC + brain microvessels (data not shown). When excluding
Figure 1 Induction of vascular Darc expression during EAE. In
situ hybridization analysis for Darc in the cerebellum of an SJL
mouse with EAE (Day 14, clinical score 2) and in a healthy
control mouse. A specific hybridization signal for Darc can be
localized to inflamed vessels in the EAE brain but not the control
brain with the anti-sense (as) probe. Note the additional specific
hybridization signal on cerebellar neurons of the granule cell
layer in the right lower corner. Control in situ hybridization using
the sense (s) probe did not produce any signal. Sections were
counterstained with Toluidine blue. Left: Bright field images.
Right: Dark field images. Top: Enlarged bright field image
showing Darc-specific hybridization on inflamed brain vessel
during EAE. Scale bar = 50mm. One experiment out of two
analysing two mice per group is shown.
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these controls, quantification showed a comparable collagen IV-
positive vessel density in subcortical white matter between con-
trols and patients with multiple sclerosis and identified a higher
number of DARC-positive vessels in multiple sclerosis than in con-
trol white matter (Fig. 3G). Furthermore, the higher number of
DARC-positive vessels detected in multiple sclerosis tissue was
equally observed in normal appearing white matter, chronic
active lesions and chronic inactive lesions (Fig. 3). Taken together
these findings show that DARC is expressed in a subset of brain
micovessels in humans. In chronic neuroinflammatory diseases,
including multiple sclerosis, a significantly higher number of
DARC-positive microvessels could be detected, corresponding to
our findings in EAE.
Endothelial DARC shuttles
inflammatory chemokines across the
blood–brain barrier in vitro
A proinflammatory role for endothelial DARC in EAE pathogenesis
could be envisaged such that DARC transports chemokines from
the abluminal to the luminal side of the blood–brain barrier and
thus facilitates leucocyte trafficking across this vascular barrier. As
this hypothesis can only be directly tested in vitro by studying
chemokine transport across brain endothelial cells, we first asked
if DARC is expressed in endothelial cells used as in vitro blood–
brain barrier models such as the brain endothelioma cell line bEnd5
or pMBMECs (Steiner et al., 2011). We performed quantitative
PCR analysis of total messenger RNA preparations of bEnd5 and
of pMBMECs cultured for 6 days and of freshly isolated brain
microvessels (Fig. 4A). We found very low but measurable levels
of Darc messenger RNA in freshly isolated brain microvessels
arguing for a low constitutive expression of Darc messenger
RNA in brain endothelial cells in vivo. bEnd5 as well as
pMBMECs cultured for 6 days expressed Darc messenger RNA
and 16 h of TNF treatment further increased the messenger
RNA levels to almost 10-fold, confirming that expression of Darc
messenger RNA is upregulated in inflamed CNS microvascular
endothelial cells. Immunostaining of pMBMECs isolated from
wild-type SJL mice and Darc/ SJL mice as a negative control,
confirmed cell surface protein expression of DARC on wild-type
pMBMECs after stimulation with TNF (Fig. 4B), whereas specific
immunostaining for DARC could not be observed on non-stimu-
lated pMBMECs (data not shown). Thus, upregulated expression
of Darc messenger RNA was accompanied by increased cell sur-
face expression of DARC protein on inflamed pMBMECs in vitro.
To ensure that lack of DARC in brain endothelial cells does not
influence barrier characteristics of brain endothelial cells per se and
would then lead to increased diffusion of chemokines across the
Darc/ endothelial barrier, we investigated the paracellular per-
meability for small molecular tracers in the size range of chemo-
kines, namely 3 kDa and 10 kDa dextran, across pMBMECs
isolated from wild-type and Darc/ SJL mice. We found no sig-
nificant differences in the paracellular permeabilities for 3 kDa
Figure 2 Detection of DARC at the protein level on inflamed CNS vessels. Immunofluorescence staining of frozen spinal cord tissue
sections at different time points during EAE pathogenesis of wild-type C57BL/6 mice. Mice were immunized with MOG35-55 peptide
emulsified in complete Freund’s adjuvant and tissues were prepared at Day 7, Day 11 and Day 13 post-immunization. Triple immuno-
fluorescence staining for PECAM1 (blue), CD45 (green) and DARC (red). Specific immunostaining for DARC was detectable at Day 7 after
induction of EAE. Scale bar = 20 mm. One experiment out of three analysing three mice per time point is shown.
DARC in EAE Brain 2014: 137; 1454–1469 | 1459
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Figure 3 DARC expression in human subcortical white matter of control and multiple sclerosis cases. Immunohistochemical analysis of
brain vessels within the human cortex from multiple sclerosis (MS) cases with active inflammatory demyelinating lesion (first column, MS
lesions), within meninges (second column, MS Meninges), within normal appearing white matter (third column, MS NAWM) and from a
control case within subcortical white matter (fourth column, Control WM) are shown. MOG: MOG immunohistochemistry for myelin
differentiating demyelinating lesions from normal myelinated areas in cerebral cortex and subcortical cortical white matter in multiple
sclerosis and controls (A). DARC: DARC-positive blood vessels were detected in all areas in multiple sclerosis cases and in controls (B).
CD68: CD68 immunohistochemistry detects inflamed blood vessels (first panel) as well as activated microglia throughout the white matter
(C). HE: Histology shown by haematoxylin and eosin staining of the corresponding area (D). Scale bar = 50 mm. Bottom: Collagen IV
immunohistochemistry in multiple sclerosis normal appearing white matter identifying all blood vessels (E), whereas DARC staining could
only be detected in a subset of blood vessels (F, arrows). DARC immunoreactivity was detected in larger (large arrow, higher magnification
in inset) as well as in smaller blood vessels (small arrow). Insets show area around the blood vessel highlighted by the large arrow.
Arrowhead points to a blood vessel, which is DARC-negative. Scale bar = 500 mm. (G) Quantification showing more DARC-positive blood
vessels in multiple sclerosis normal appearing white matter compared with control white matter (P-value = 0.0282).
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(data not shown) and 10 kDa (Fig. 4C) dextrans between non-
stimulated or TNF- stimulated pMBMECs isolated from wild-
type or Darc/ SJL mice. Thus absence of DARC did not influ-
ence barrier integrity of brain endothelial cells in vitro.
In addition, brain endothelial cells have been described to ex-
press, upon stimulation, inflammatory chemokines such as CCL2.
Endogenous chemokine expression could thus impair the analysis
of exogenous chemokine transport across the blood–brain barrier
in vitro. We therefore tested production of the chemokines CCL2
(JE), CCL5 (RANTES) and CXCL1 (KC), which we previously found
to be upregulated in inflamed CNS microvessels during EAE (Alt
et al., 2005) and the homeostatic chemokine CCL21, which does
not bind DARC, as a control from wild-type and Darc/
pMBMECs grown on filters and stimulated or not with TNF-
Figure 4 Characterization of Darc/ in vitro blood–brain barrier models. (A) Quantitative PCR analysis of Darc messenger RNA
expression in bEnd5, freshly isolated and cultured pMBMECs. bEnd5 and pMBMECs were cultured for 6 days and were either TNF (16 h)
stimulated or not. Freshly isolated brain microvessels were used as a control. Quantitative PCR was performed with two different primer
pairs (911/912, 913/914) and Darc expression levels are shown relative to that of unstimulated pMBMECs (set to 1.0). Stimulation with
TNF upregulated Darc messenger RNA expression in bEnd5 (10-fold) and in pMBMECs (5- to 6-fold). One experiment out of two with
comparable results is shown. (B) Immunostaining for DARC on pMBMECs. pMBMECs from wild-type SJL (wt; upper panel) and Darc/
SJL (DARC/ ; lower panel) mice were cultured for 6 days on matrigel-coated permanox chamber slides and were TNF stimulated 16 h
before staining. Positive and specific immunostaining for DARC with the rabbit anti-mouse DARC antibody could only be observed on
individual TNF stimulated pMBMECs from wild-type SJL mice as indicated by white arrowheads (top left) despite high background
staining observed using rabbit IgG. We did not observe DARC-immunostaining on non-stimulated pMBMECs (data not shown). Scale
bars = 20 mm. (C) Dextran (10 kDa) permeability across wild-type and DARC-deficient pMBMECs. The permeability coefficients Pe of
10 kDa dextran for unstimulated and stimulated pMBMECs from wild-type (SJL-TNF and SJL + TNF) or DARC-deficient (D/-TNF and
D/ + TNF) SJL mice are shown. Bars represent mean  SEM of three independent experiments. No statistically significant differences
of Pe between unstimulated or TNF- stimulated pMBMECs from Darc/ and wild-type SJL mice were observed. (D) CCL2 chemokine
secretion of pMBMECs. CCL2 chemokine secretion of DARC-deficient (D/ ) and wild-type (SJL) SJL pMBMECs stimulated ( + TNF) or
not (-TNF) with TNF for 16 h was determined after 3 h by ELISA. The total amount of chemokine found in the upper compartment
(150 ml) was calculated and the bars show mean  SD. A significant difference in CCL2 production between TNF- stimulated DARC/
and wild-type pMBMECs was found. *P50.05. One experiment out of three with reproducible results is shown. rb = rabbit.
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after a 3 h and 16 h timespan. Analysing the culture supernatants of
pMBMBEs by ELISA we did not detect measurable levels of CCL21
and CXCL1 either at 3 h or at 16 h of incubation (data not shown).
CCL5 was detected in supernatants of TNF- stimulated wild-type
and Darc/ pMBMECs at 16 h but not at 3 h, reaching a maximal
concentration of 0.1 ng/150 mL. In contrast we found that wild-type
and Darc/ pMBMECs constitutively produced up to 0.8 ng/
150 ml CCL2 within 16 h and up to 2.5 ng/150 mL when previously
stimulated with TNF-. However, within 3 h, the time window
required to study exogenous chemokine transport across the
blood–brain barrier in vitro, CCL2 production remained very low
reaching a maximum of 0.3 ng/150 microliters in TNF stimulated
pMBMECs (Fig. 4D). Interestingly, CCL2 production of TNF stimu-
lated Darc/ pMBMECs remained significantly lower when com-
pared with TNF stimulated wild-type pMBMECs. In any case, we
felt confident to investigate the transport of exogenously added
chemokines across pMBMECs within a timeframe of 3 h in vitro.
The inflammatory chemokines CCL2, CCL5 and CXCL1 are po-
tential ligands for DARC, whereas the homeostatic chemokine
CCL21 does not bind DARC. We therefore investigated the trans-
port of these chemokines from the abluminal to the luminal com-
partment across pMBMECs from wild-type and Darc/ SJL mice
grown on filter inserts and stimulated or not for 16 h with TNF.
Thirty nanograms of the respective recombinant chemokine was
added to the lower compartment of the two chamber transwell
assay system and samples from the upper compartment were
taken at 1, 2 and 3 h of incubation, frozen immediately and
later analysed by ELISA. Transport of CCL21 across pMBMECs
was very low and as expected, we found no difference in the
transport of CCL21 from the abluminal to the luminal compart-
ment between wild-type and Darc/ pMBMECs (Fig. 5).
Transport of CCL21 was also not increased across TNF stimulated
pMBMECs. Although human DARC binds CXCL1 with high affin-
ity (Gardner et al., 2004), transport of murine CXCL1 across
Figure 5 DARC shuttles CCL2 and CCL5 across the inflamed blood–brain barrier in vitro. Transport of recombinant chemokines from the
basolateral to the luminal side of wild-type SJL pMBMECs (SJL, black lines) or Darc/ SJL pMBMECs (D/ , grey lines) with ( + TNF)
or without (TNF) TNF-stimulation is shown. Samples were taken at 1, 2 and 3-h time points and analysed in triplicates by ELISA. ELISA
data were analysed using Instat Prism and Microsoft Excel and the total amount of chemokine, which was translocated to the upper
compartment, was calculated. Translocation of CCL2 and CCL5 across TNF stimulated SJL pMBMEC was found to be significantly
increased (solid black lines) correlating with induction of DARC expression after TNF stimulation. CXCL1 and CCL21 were not trans-
located in a DARC-dependent manner. One out of three independent experiments is shown. Data were analysed using Instat Prism and
Microsoft Excel. Line graphs show mean  SD.
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pMBMECs was observed to be equally low as that of CCL21 and
was independent of the expression of DARC (Fig. 5). In contrast,
transport of CCL5 and CCL2 was generally more efficient and
found to be significantly increased across TNF- stimulated
pMBMECs from wild-type SJL mice but not from Darc/ SJL
mice when compared to the respective non-stimulated
pMBMECs (Fig. 5). As we found expression of DARC to be upre-
gulated on pMBMECs after TNF stimulation (Fig. 4A), these ob-
servations demonstrate an active role for endothelial DARC in
mediating the transport of CCL2 and CCL5 but not of CXCL1
from the abluminal to the luminal side of pMBMECS. These
data therefore support a pro-inflammatory function of DARC ex-
pressed in brain endothelial cells in EAE pathogenesis by shuttling
chemokines across the blood–brain barrier.
Darc/ C57BL/6 and Darc/ SJL
mice develop ameliorated experimental
autoimmune encephalomyelitis
To investigate the functional contribution of DARC in EAE patho-
genesis we next investigated if development of EAE is impaired in
the absence of DARC. To this end Darc/ mice were back-
crossed into the EAE susceptible mouse stains C57BL/6 and SJL
for at least 10 generations and the development of actively in-
duced EAE was compared in Darc/ C57BL/6 and Darc/ SJL
mice and the respective C57BL/6 and SJL wild-type littermate
control mice. Although we did not observe a significant difference
in disease onset, Darc/ C57BL/6 and Darc/ SJL mice de-
veloped a milder clinical disease during the first clinical episode
of EAE when compared with the respective wild-type control
mice (Fig. 6). Furthermore, Darc/ C57BL/6 maintained a
milder chronic disease compared to wild-type C57BL/6 mice,
and Darc/ SJL mice completely recovered before developing a
milder relapse when compared with wild-type SJL mice (Fig. 4).
Using the area under the curve as a measure for overall disease
activity (Fleming et al., 2005), we found a significantly reduced
severity of clinical EAE in Darc/ C57BL/6 and Darc/ SJL mice
compared with their respective wild-type littermates of the same
strain supporting a functional role of DARC in EAE pathogenesis.
Immunohistological stainings for CD45 + inflammatory infiltrates
and for CD3 + T cells, B220+ B cells, Gr1 + and CD11b + myeloid
cells in brain and spinal cord sections of wild-type and Darc/
C57BL/6 and SJL mice during the peak of EAE suggested the pres-
ence of smaller inflammatory infiltrates in Darc/ SJL and Darc/
C57BL/6 mice when compared with wild-type controls, however,
we did not observe striking differences in the number of inflam-
matory cuffs or their cellular composition (data not shown).
Darc/ mice C57BL/6 mice have no
defect in antigen-specific T cell priming
and proliferation
Expression of DARC was previously described on high endothelial
venules in peripheral lymph nodes (Kashiwazaki et al., 2003). We
confirmed specific immunostaining for DARC on high endothelial
venules in pheripheral lymph nodes of healthy C57BL/6 and SJL
mice using our novel anti-mouse DARC antibody (data not
shown). We first asked if expression of DARC is altered in draining
lymph nodes after induction of EAE. By performing immunostainings
on frozen tissue sections of draining lymph nodes taken from C57BL/
6 mice at Days 6, 10 and 14 after subcutaneous immunization with
MOGaa35–55 in complete Freund’s adjuvant we found no difference
in high endothelial venule-specific immunostaining for DARC (data
not shown). As absence of DARC could influence lymphocyte recir-
culation through non-inflamed or inflamed lymph nodes, we asked if
absence of DARC on the high endothelial venules might influence
the priming and proliferation of encephalitogenic T cells after induc-
tion of EAE. To this end Darc/ C57BL/6 mice and wild-type
C57BL/6 mice were subcutaneously immunized with MOGaa35–55/
complete Freund’s adjuvant and subsequently we performed anti-
gen-recall proliferation assays with lymph node cell suspensions from
draining lymph nodes at Days 6 and 9 post-immunization. We
observed comparable MOGaa35-55 specific T cell proliferation re-
sponses in wild-type and Darc/ C57BL/6 mice (Fig. 7) and there-
fore conclude that priming and proliferation of encephalitogenic T
cells is not impaired in the absence of DARC.
DARC regulates increased plasma levels
of chemokines during experimental
autoimmune encephalomyelitis
In addition to endothelial DARC, availability of inflammatory che-
mokines within the blood stream can be regulated by erythrocyte
DARC. Erythrocyte DARC has been reported to serve as a blood
reservoir for inflammatory chemokines but at the same time also
as a chemokine sink that buffers increases in plasma chemokine
levels. To determine the influence of DARC on the presence of
circulating chemokines we asked if the inflammatory chemokines
CCL2, CCL5 and CXCL1, which we also investigated for their
DARC-mediated transport across the blood–brain barrier, can be
detected in the plasma of Darc/ and wild-type C57BL/6 mice
during EAE. Using a mouse cytokine array we detected CXCL1
and CCL2 in the plasma of C57BL/6 mice but not of Darc/
C57BL/6 mice at the clinical onset (Day 10 post-immunization) of
EAE (Fig. 8A). In contrast, CCL5 was not detected in plasma sam-
ples of both Darc/ and wild-type C57BL/6 mice. Soluble
ICAM1 was investigated as a marker of inflammation and positive
control and was observed at comparable levels in the plasma of
Darc/ and wild-type C57BL/6 mice (Fig. 8A). Thus, in the ab-
sence of DARC, neuroinflammation is not accompanied by the
occurrence of increased levels of inflammatory chemokines in
the plasma supporting the notion that DARC serves as a blood
reservoir for inflammatory chemokines.
To understand if absence of inflammatory chemokines in the
plasma of Darc/ C57BL/6 mice during EAE is because of the
lack of vascular or erythrocyte DARC we generated reciprocal
bone marrow chimeras by transferring bone marrow cells from
Darc/ C57BL/6 mice into lethally irradiated wild-type C57BL/
6 mice and vice versa. Eight weeks after recovery, active EAE was
induced by subcutaneous immunization with MOGaa35–55 in com-
plete Freund’s adjuvant and plasma samples were collected, and
immediately frozen, from the four groups of mice at different days
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(Days 6, 10, 14 and 35) post-immunization. In addition we col-
lected plasma samples from non-immunized mice to determine the
chemokine plasma concentrations of healthy bone marrow chi-
meric mice. All plasma samples were tested for CCL2, CCL5 and
CXCL1. CCL5 could not be detected in any of the plasma samples
investigated. In contrast, very low levels of CCL2 (550 pg/ml) and
low levels of CXCL1 (5500 pg/ml) were already detected in
plasma samples in all four groups of non-immunized mice, prob-
ably because of the higher sensitivity of the ELISA when compared
with the cytokine microarray performed previously (Fig. 8B). After
induction of EAE we found significantly increased plasma levels of
CXCL1 in both groups of bone marrow chimeric mice expressing
DARC on erythrocytes but not in bone marrow chimeric mice
lacking erythrocyte DARC, which underscores a role for erythro-
cyte DARC as a blood reservoir for CXCL1. Increased levels of
CXCL1 were detectable on Day 6 post-immunization, before the
onset of EAE, and remained elevated on Day 10 post-immuniza-
tion, coinciding with the onset of clinical EAE. At Day 14 post-
immunization, plasma levels of CXCL1 declined to baseline levels
(Fig. 8B).
CCL2 plasma concentrations detected in non-immunized bone
marrow chimeric mice were 10-fold lower when compared with
CXCL1. After induction of EAE, plasma concentrations of CCL2
slightly increased in a similar kinetic in all four groups of chimeric
mice reaching significantly increased levels of CCL2 when compared
with non-immunized mice at the onset of EAE (Day 10 post-immun-
ization), decreasing to baseline levels at Day 14 post-immunization,
and remaining low until Day 35 post-immunization during chronic
EAE. At none of the time points investigated did plasma levels of
CCL2 significantly differ between the four groups of bone marrow
chimeric mice (Fig. 8B) suggesting that plasma levels of CCL2 do not
critically rely on the expression of DARC.
Figure 6 Darc/ SJL or Darc/ C57BL/6 mice develop ameliorated EAE. (A) In Darc/ C57BL/6 mice (backcrossing generation N12)
and wild-type C57BL/6 littermates active EAE was induced by subcutaneous immunization with MOGaa35–55 in complete Freund’s
adjuvant. The left graph shows mean disease scores of 10 animals per group  SEM, evaluated daily following induction of EAE. (B) In
Darc/ SJL mice (backcrossing generation N10) active EAE was induced by subcutaneous immunization with PLP139-151 in complete
Freund’s adjuvant. The left graph shows mean disease scores of nine animals per group  SEM, evaluated daily following induction of
EAE. The bar graphs show the area under the curve (AUC) calculated from the EAE clinical course for each mouse between Days 0–42 (A)
or Days 0–45 (B) post-immunization. Shown are the mean area under the curve values for each group  SD. Statistical analysis of area
under the curve values with the Mann-Whitney test revealed significantly reduced EAE severity in Darc/ mice (grey bars) compared to
wild-type controls (black bars) mice in both C57BL/6 mice (A) and SJL mice (B). *P50.05. (A) One experiment out of three including a
total of 26 Darc/ C57BL/6 and wild-type C57BL/6 mice, respectively is shown. (B) One experiment out of three including a total of 24
Darc/ SJL and wild-type SJL mice, respectively is shown.
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Absence of endothelial DARC
ameliorates experimental autoimmune
encephalomyelitis
Having established apparently opposing roles of endothelial and
erythrocyte DARC with vascular DARC shuttling CCL2 but not
CXCL1 across the blood–brain barrier and erythrocyte DARC
maintaining increased plasma levels of CXCL1 but not of CCL2,
we finally asked if ameliorated EAE is due to the lack of endothe-
lial or erythrocyte DARC. To distinguish between a role of erythro-
cyte and endothelial DARC to EAE pathogenesis, we generated
reciprocal bone marrow chimeras by transferring bone marrow
cells from Darc/ C57BL/6 mice into lethally irradiated wild-
type C57BL/6 mice and vice versa. After a recovery for 8
weeks, active EAE was induced in bone-marrow chimeric mice
by subcutaneous immunization with MOGaa35–55 in complete
Freund’s adjuvant. Darc/ C57BL/6 mice, reconstituted with
either Darc/ or wild-type C57BL/6 bone marrow cells,
showed a delayed onset of EAE when compared with wild-type
C57BL/6 mice reconstituted with either Darc/ or wild-type
C57BL/6 bone marrow cells (Fig. 9A) and an ameliorated disease
as determined by the area under the curve (Fig. 9B). These ob-
servations supported our previous observations of ameliorated EAE
in Darc/ C57BL/6 mice compared with wild-type C57BL/6 mice
Figure 8 DARC regulates increased plasma levels of chemo-
kines during EAE. (A) Mouse cytokine array analysing plasma
samples prepared from Darc/ C57BL/6 and wild-type C57BL/
6 mice 10 days post-immunization (p.I.) with MOGaa35–55 in
complete Freund’s adjuvant. CCL2 and CXCL1 were found in
the plasma of wild-type C57BL/6 mice but were absent in the
plasma of Darc/ C57BL/6 mice. Soluble ICAM1 was chosen
as a DARC-independent positive control and detected with
comparable signal intensities in both Darc/ C57BL/6 mice
and wild-type C57BL/6 controls. One out of two independent
experiments is shown. (B) CXCL1 (top) and CCL2 (bottom)
plasma levels of bone marrow chimeric mice at different time
points during EAE pathogenesis measured by ELISA are shown.
White bar = Darc/ BM:Darc/ (Darc/ C57BL/6 mice
reconstituted with Darc/ bone marrow); light grey
bar = Darc/ BM:C57 (C57BL/6 mice reconstituted with
Darc/ bone marrow), dark grey bar = C57 BM: Darc/
(Darc/ C57BL/6 mice reconstituted with C57BL/6 bone
marrow), black bar = C57 BM: C57 (C57BL/6 mice reconstituted
with C57BL/6 bone marrow). Bars show mean  SD. Number of
samples for CXCL1: non-immunized mice (n.i.) and Day 6 post-
immunization n = 4; Days 10 and 14 post-immunization n = 6.
Number of samples for CCL2: n = 4 for all timepoints. *Bordered
line P5 0.05 between both groups of wild-type and Darc/
BM recipients; *simple line P50.05 between the individual
columns. Significantly elevated plasma levels of CXCL1 were
only detected in the presence of erythrocyte DARC starting at
Day 6 post-immunization before onset of clinical EAE.
Figure 7 Lack of DARC does not alter antigen-induced T cell
proliferation in C57BL/6 mice. Plots show MOGaa35–55 peptide
induced T cell proliferation of primary cultures from draining
lymph node lymphocytes prepared 6 days (A) and 9 days (B)
post-immunization of Darc/ C57BL/6 mice and wild-type
C57BL/6 mice upon stimulation with increasing MOGaa35–55
peptide concentrations (mean  SD). MOG-specific prolifer-
ation was normalized against baseline proliferation. Proliferation
was measured by 3H-dT incorporation. One representative ex-
periment out of six is shown.
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(Fig. 6) and demonstrated that absence of endothelial but not
erythrocyte DARC is required for establishing ameliorated
EAE (Fig. 9). These observations underscore the pro-inflammatory
role of DARC by shuttling chemokines across the blood–brain
barrier.
Discussion
DARC belongs to the family of atypical ‘silent’ chemokine chemo-
kine receptors, which are structurally similar to other G-protein
coupled receptors with seven transmembrane spanning helices
and extracellular domains binding chemokines with high affinity.
In contrast with other chemokine receptors, atypical chemokine
receptors including DARC fail to engage G-proteins and therefore
do not couple to signalling cascades inducing integrin activation
and cell motility. The inability to trigger conventional chemokine
responses has led to concepts of chemokine scavenging, seques-
tration, buffering and transcellular transport by these atypical che-
mokine receptors. It has been shown that human DARC can bind
many, but not all pro-inflammatory CC and CXC chemokines
(Gardner et al., 2004). Depending on its cellular expression, the
biological functions assigned to DARC have been quite different.
Whereas erythrocyte DARC was shown to bind chemokines and
either serve as a sink or a reservoir for inflammatory chemokines in
the circulation, endothelial DARC was described to internalize and
transcytose chemokines from their parenchymal sites of synthesis
to the luminal side of the endothelium, where the chemokines
were found immobilized and could contribute to leucocyte ex-
travasation in vivo (Novitzky-Basso and Rot, 2012).
Based on these findings we considered DARC to be a candidate
molecule mediating during neuroinflammation the transport of
CNS-derived inflammatory chemokines across the highly specia-
lized and polarized endothelial cells forming the blood–brain bar-
rier. Our present study demonstrates that DARC is upregulated on
endothelial cells in CNS microvessels during EAE and in multiple
sclerosis and contributes to EAE pathogenesis. Although erythro-
cyte DARC served as a chemokine reservoir during EAE, brain
endothelial DARC was found to shuttle recombinant chemokines
from the abluminal to the luminal side of an in vitro blood–brain
barrier model. Absence of endothelial, but not erythrocyte DARC,
was responsible for amelioration of EAE in line with a contribution
of endothelial DARC in shuttling inflammatory chemokines from
the CNS parenchyma across the blood–brain barrier influencing
immune cell interaction with the inflamed blood–brain barrier
during EAE and multiple sclerosis.
The infiltration of immune cells into the CNS is an essential step
in the neuropathogenesis of multiple sclerosis and its animal model
EAE. Live cell imaging studies observing the interaction of ence-
phalitogenic T cells with brain or spinal cord microvessels during
EAE demonstrated the prerequisite of G-protein coupled receptor
signalling for the integrin-mediated firm arrest of T cells to the
inflamed CNS microvessels (Vajkoczy et al., 2001; Piccio et al.,
2002). These observations suggested the involvement of chemo-
kines available on the luminal surface of the blood–brain barrier
endothelium in T cell trafficking across the blood–brain
barrier. Glycosaminoglycans (GAGs), most importantly heparan
Figure 9 Lack of vascular DARC ameliorates EAE. MOG35–55 peptide-induced active EAE in bone marrow chimeric mice (backcrossing
generations N11 to N14) is shown. (A) The graph shows mean disease scores of five animals per group  SEM, evaluated daily following
induction of EAE. Darc/ C57BL/6 mice reconstituted with Darc/ bone marrow (DARC/!DARC/ ; grey filled circles) or
C57BL/6 wild-type bone marrow (BL/6!DARC/ ; black grey semi-filled circles) developed ameliorated EAE when compared to
C57BL/6 mice reconstituted with either C57BL/6 bone marrow (BL6!BL6; black filled squares) or Darc/ bone marrow
(DARC/!BL/6; grey/black semi-filled squares). (B) Area under the curve (Days 0–16 post-immunization) as a measure for overall
disease severity was calculated and found to be significantly reduced (*P50.05) in Darc/ C57BL/6 mice reconstituted with either wild-
type or Darc/ bone marrow, when compared to wild-type recipients irrespective of reconstitution with wild-type or Darc/ bone
marrow. One experiment out of three investigating a total of 10 to 14 mice for each group is shown.
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sulphates, are abundant on the luminal surface of endothelial cells
including brain endothelial cells, and have been shown to avidly
bind chemokines (Parish, 2006). Luminal presence of CCL2 and
CCL5 on the blood–brain barrier has been suggested by live cell
imaging studies demonstrating that antibodies blocking CCL2 and
CCL5 prevented leucocyte adhesion but not rolling in the inflamed
brain microvasculature during EAE (dos Santos et al., 2005).
Interestingly, although expression of CCL2 and CCL5 can read-
ily be detected in cultured brain endothelial cells in vitro (Holman
et al., 2011), in multiple sclerosis lesions and in EAE, both chemo-
kines are expressed rather by astrocytes or infiltrating immune cells
(Ubogu et al., 2006). In contrast, expression of the homeostatic
chemokines CCL19 and CCL21 was found to be upregulated in
brain endothelial cells in a mouse model of EAE (Alt et al., 2002)
and in multiple sclerosis lesions (Krumbholz et al., 2007), but their
involvement in leucocyte migration across the blood–brain barrier
during neuroinflammation remains to be shown. In addition,
increased CNS expression of CXCL12 in EAE and multiple sclerosis
was found to be accompanied by the loss of polarized expression
of this chemokine in CNS microvascular endothelial cells
(McCandless et al., 2006, 2008). CXCL12 might therefore
become luminally available during neuroinflammation and mediate
T cell arrest to the inflamed blood–brain barrier in EAE and mul-
tiple sclerosis (McCandless et al., 2006, 2008; Moll et al., 2009).
In addition to homeostatic chemokines, there is abundant evi-
dence for the involvement of inflammatory chemokines and their
receptors e.g. CCR1 (Rottman et al., 2000), CCR2 (Fife et al.,
2000; Izikson et al., 2000) and CXCR2 (Carlson et al., 2008), in
the pathogenesis of EAE and multiple sclerosis (Ubogu et al.,
2006). Intriguingly, most of the chemokines shown to be involved
in EAE pathogenesis are expressed by glial cells or inflammatory
cells localized in the CNS parenchyma in EAE brains and multiple
sclerosis lesions (Glabinski et al., 1998; Sorensen et al., 1999; Lund
et al., 2004; Omari et al., 2006). Considering the unique barrier
characteristics of the brain endothelial cells it is highly unlikely that
sufficient amounts of these chemokines diffuse across the blood–
brain barrier to target circulating immune cells into the CNS. Thus,
the contribution of inflammatory chemokines to the pathogenesis
of multiple sclerosis and EAE by mediating the migration of circu-
lating leucocytes across the blood–brain barrier into the CNS re-
quires the existence of a putative transport mechanism for
inflammatory chemokines from the abluminal to the luminal side
of the blood–brain barrier endothelium.
In fact it has been demonstrated that CCL2 can be transported
from the abluminal to the luminal side of brain microvascular
endothelial cells by a transcellular mechanism that at least in
part involves binding of CCL2 to CCR2 and caveolae (Dzenko
et al., 2001; Ge et al., 2008).
Another potential candidate molecule able to transport chemo-
kines across the blood–brain barrier is the atypical chemokine re-
ceptor DARC, which binds most inflammatory chemokines. DARC
is expressed in microvascular endothelial cells in peripheral organs
and the current view is that DARC can mediate the transcellular
transport of chemokines across vascular barriers. Support for this
view came from elegant in situ studies that followed the traffick-
ing of radiolabelled chemokines in skin explants from the intersti-
tial space through the vesicular network of endothelial cells to the
luminal surface of venules where they co-localized with DARC
immunoreactivity (Middleton et al., 1997; Hub and Rot, 1998;
Pruenster et al., 2009). In heterologous transfectants DARC was
shown to relocalize from the basolateral to the apical side through
an intracellular vesicular compartment upon binding of inflamma-
tory chemokines (Pruenster et al., 2009). In this study it was also
shown that the functional chemokines translocated with DARC.
The precise mechanism of DARC-mediated chemokine transcytosis
remains to be investigated. Although some studies localized DARC
to caveolin 1 and therefore to caveolae as vesicular transport com-
partment (Luo et al., 1997; Middleton et al., 1997) DARC-
mediated chemokine endocytosis seems to occur through a
macropinocytosis-like process in endothelial cells for which caveo-
lin 1 was dispensable (Zhao et al., 2011).
These findings prompted us to investigate if DARC is also ex-
pressed at the blood–brain barrier and could serve as a chemokine
shuttle across the blood–brain barrier during neuroinflammation.
In a gene expression profiling study we identified upregulated
expression of DARC in cerebral microvessel preparations from
C57BL/6 and SJL mice suffering from EAE compared with micro-
vessel preparations of healthy control mice (Alt et al., 2005). A
similar approach confirmed upregulated expression of DARC in
acute white matter lesions in the brain of a patient with multiple
sclerosis, when compared with normal-appearing white matter
(Whitney et al., 1999). Performing in situ hybridization and immu-
nohistology in the present study we demonstrate increased ex-
pression and immunostaining of DARC in CNS microvessels
starting before the clinical onset of EAE. As most of the inflam-
matory chemokines involved in EAE pathogenesis are upregulated
in the CNS during preclinical stages already (Carlson et al., 2008)
this finding further supports a potential involvement of endothelial
DARC in shuttling inflammatory chemokines from the CNS paren-
chyma to the luminal surface of the blood–brain barrier. Detection
of increased DARC immunostaining in brain microvessels in acute
lesions of multiple sclerosis brains further corroborates the contri-
bution of DARC to autoimmune neuroinflammation. Using a well-
differentiated mouse in vitro blood–brain barrier model that has
proven to reliably mimic blood–brain barrier characteristics under
physiological and pathological conditions (Coisne et al., 2005,
2013; Enzmann et al., 2013), we found that expression of
DARC in brain endothelial cells is upregulated by proinflammatory
stimuli and that expression of endothelial DARC correlates with
increased basolateral to luminal transport of recombinant CCL2
and CCL5 but not of CXCL1 in vitro. As to date there are no
binding studies investigating the interaction of mouse DARC with
mouse chemokines, the affinity of CXCL1 to murine DARC is un-
known. In contrast, human DARC has been shown to bind CCL2,
CCL5 and CXCL1 with similarly high affinities (Gardner et al.,
2004). As we used recombinant chemokines in this assay, which
might be different from endogenous chemokines in their post-
translational modifications including but not limited to their glyco-
sylation patterns, one could speculate that post-translational modi-
fication of recombinant CXCL1 might not be favourable for DARC
binding. Finally, our in vitro studies investigating DARC-mediated
chemokine shuttling across the blood–brain barrier have employed
recombinant chemokines,
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It is noteworthy, however, that the amounts of CXCL1 we
found to be shuttled across the tight brain endothelial cell mono-
layers in vitro independent of DARC expression were in general 5-
to 10-fold below those detected for CCL5 and CCL2, respectively.
In contrast, when studying the role of erythrocyte DARC during
EAE in reciprocal bone marrow chimeras we found plasma levels
of soluble endogenous CXCL1 but less so of CCL2 to strictly
depend on erythrocyte but not on endothelial DARC. This could
be due to a different glycosylation status of the respective che-
mokines within the circulation versus the inflamed CNS paren-
chyma, which might differentially influence chemokine binding
to endothelial versus erythrocyte DARC. In any case, these find-
ings confirm the function of erythrocyte DARC as a chemokine
reservoir rather than a chemokine sink also in neuroinflammation.
Plasma levels of CCL2 were found be 10-fold lower than those
detected for CXCL1, which might be an alternative explanation of
the lack of a significant correlation of increased CCL2 plasma
levels with erythrocyte DARC in EAE.
In contrast, increased plasma levels of CXCL1 were detected in
bone marrow chimeric mice expressing erythrocyte DARC before
the onset of the clinical disease 6 days after the induction of EAE.
As CXCL1 can be induced by IL17 it is tempting to speculate that
in contrast to CCL2, CXCL1 might be induced by encephalitogenic
TH17 cells in peripheral tissues and thus might readily be detected
in the plasma of mice expressing erythrocyte DARC (Onishi and
Gaffen, 2010).
Involvement of DARC in EAE pathogenesis is demonstrated
by our findings that absence of DARC ameliorates chronic
EAE in C57BL/6 mice and relapsing-remitting EAE in SJL/ mice.
When addressing the impact of erythrocyte DARC versus endo-
thelial DARC in EAE pathogenesis using reciprocal bone marrow
chimeric mice, we found that absence of endothelial rather than
erythrocyte DARC ameliorated the disease course. Although our
findings confirmed an important role of erythrocyte DARC as a
chemokine reservoir in the blood stream during EAE, this function
of DARC seems to have no significant influence in EAE patho-
genesis. In contrast, endothelial DARC contributes to EAE
pathogenesis by shuttling chemokines across the blood–brain
barrier.
In summary our study demonstrates the involvement of endo-
thelial DARC in mediating the transport of inflammatory chemo-
kines across the blood–brain barrier during neuroinflammation and
its impact in disease severity and progression.
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